What Is Lunsumio Velo, and Why Does It Matter? Lunsumio Velo (mosunetuzumab-axgb) is a new under-the-skin (subcutaneous) injection version of the anticancer medicine Lunsumio intravenous infusion. The ...
While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...
Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 ...
Studies demonstrating high response rates and manageable safety profiles, along with FDA approvals, have supported bispecific antibodies as promising treatment options for follicular lymphoma. At the ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
"Random skin biopsies are utilized when there is a sufficiently high concern of the diagnosis in the patient and they do not have overt clinical findings suggestive of the diagnosis. In those cases, ...
Please provide your email address to receive an email when new articles are posted on . With new developments in the treatment of follicular lymphoma, such as chimeric antigen receptor T-cell ...
Lymphoma in the legs can cause swelling and skin rashes in addition to fever, unintentional weight loss, and fatigue. Treatment may include chemotherapy, radiation, and stem cell transplants. Your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback